Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.
about
Methotrexate and PralatrexatePredictive Modeling of Drug Response in Non-Hodgkin's LymphomaTreatment of peripheral T-cell lymphoma: are we data driven or driving the data?Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL studyPhase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma.Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma.Pralatrexate : evaluation of clinical efficacy and toxicity in T-cell lymphoma.A phase 1 clinical trial of sequential pralatrexate followed by a 48-hour infusion of 5-fluorouracil given every other week in adult patients with solid tumors.Preemptive leucovorin administration minimizes pralatrexate toxicity without sacrificing efficacy.Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancerThe human proton-coupled folate transporter: Biology and therapeutic applications to cancer.Peripheral T-cell lymphoma: review and updates of current management strategiesNew strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapiesEvolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)Novel therapeutics for aggressive non-Hodgkin's lymphoma.An update on the management of peripheral T-cell lymphoma and emerging treatment optionsSafety and efficacy of pralatrexate in the management of relapsed or refractory peripheral T-cell lymphomaHow to predict the outcome in mature T and NK cell lymphoma by currently used prognostic models?Clinical Trials and Treatment of ATL.Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project.Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.The antifolatesThe membrane transport and polyglutamation of pralatrexate: a new-generation dihydrofolate reductase inhibitorDistinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers.The major facilitative folate transporters solute carrier 19A1 and solute carrier 46A1: biology and role in antifolate chemotherapy of cancer.Pralatrexate: basic understanding and clinical development.The emerging role of histone deacetylase inhibitors in treating T-cell lymphomas.Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies.New drug therapies in peripheral T-cell lymphoma.Brentuximab vedotin for the treatment of CD30+ lymphomas.Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma).Therapeutic advances in cutaneous T-cell lymphomaEnteropathy-associated T-cell lymphoma: epidemiology, clinical features, and current treatment strategies.Targeted molecular therapy in peripheral T-cell lymphomas.Update: peripheral T-cell lymphomas.Pralatrexate: a novel synthetic antifolate for relapsed or refractory peripheral T-cell lymphoma and other potential uses.Cutaneous T-cell lymphomas: a review of new discoveries and treatments.Brentuximab vedotinSafety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
P2860
Q28083080-A598E1EE-6C40-409A-B533-ADE7EB1DDD19Q28548074-C5E3879C-CC25-4C70-85BD-1C13B50572B9Q30613674-BE6F539F-028E-4BD6-B8D1-A77B87DAF491Q33393701-655BEE51-8078-4112-AB83-835049C95FCAQ33394324-8DBCA21F-4CE0-489B-9979-B3A201902C0EQ33396068-8CB16031-A791-4927-A2D6-238E91C86DF8Q33404897-813F3F4B-7BCB-47DF-BCC3-E130D6EA37BBQ33405882-735E72C2-8041-4C14-9E3B-086135DF92BEQ33424920-09130774-4062-4CED-9C24-9D4F6D83D49DQ33766600-56F1D6DB-5155-4D57-BA31-6473A91C56FDQ34019159-C296540B-8C80-4EF8-A8C3-5FE38A3078D5Q34297931-B7BF85E5-1EA9-4EF9-B76D-3090C92C0D7AQ34479082-2B382DC5-8D53-44F5-B0F8-BC82D0B3A009Q34683488-197F85CE-AB96-49A5-A63C-C1E40CFCB169Q35022833-B2B42F9A-C9C6-4738-99BB-90DBD3C27C7EQ35111768-BD4F933C-22A4-450A-A2FF-01F7960C45DCQ35683871-EC0D1463-BD51-40BC-8144-1E0ACFCC00D0Q36283958-C537AA01-7B51-48B7-94CD-C275C1BE7A66Q36355093-082E3666-A761-4F4F-86DC-1B905A4C5AD2Q36422133-83EE73D9-B69D-47F6-9854-402E2C389800Q36494259-F80743F9-E3F4-43CA-B3C3-D57D636B83C0Q36766720-A2DFE1B4-B81E-46DE-97CC-7B7B0D7A3EFFQ37183495-09BB9867-E83F-4103-AB3F-C22590EAEE02Q37200566-BD2B0BAB-856E-4E3D-8B65-70832BF28BF9Q37308731-162474B0-F36A-42D3-A6B2-C4B512513D8AQ37663377-FB71C47D-5973-453B-B45F-ABD5DE753F5BQ37761372-A4EA8A0E-1B79-4D47-A9B7-182A81CBF63AQ37809805-13313497-3516-449F-8570-383371596BE8Q37809875-24CA3E54-1847-408C-B106-64297D3D0EE8Q37854715-604A0FF4-296F-4346-8E28-D60CBBD35CB0Q37861212-3F7387B6-A80E-465A-B568-93BD3B7EA55FQ37863688-C47ED220-906A-468D-BBDA-C85198868BFFQ37876869-33CE5D65-3557-40F7-A47F-BA3991DDBBF5Q37931041-BFF9543B-99F6-4EDC-93BF-3575AC9E0006Q37937044-F2876975-61FB-4169-9EC9-49049E357D4CQ37939715-A213A92D-EC4E-4049-B064-A6F83002AAE9Q37940292-9A91BF0F-A423-4947-9698-2BC45AB951B9Q37981969-86A96159-058D-405A-AEEF-A9AE3D5E484FQ38017578-51C65F81-9CAC-4190-8C9C-302F55BC164DQ38100789-CBE8A2B6-E81A-42BE-B7CF-7E8BFB0A39DF
P2860
Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Phase II-I-II study of two dif ...... tivity in T-cell malignancies.
@en
type
label
Phase II-I-II study of two dif ...... tivity in T-cell malignancies.
@en
prefLabel
Phase II-I-II study of two dif ...... tivity in T-cell malignancies.
@en
P2093
P2860
P50
P356
P1476
Phase II-I-II study of two dif ...... tivity in T-cell malignancies.
@en
P2093
Barbara Macgregor-Cortelli
Carol Portlock
Craig H Moskowitz
Diane R Mould
Ellen Neylon
Frank Sirotnak
Jill Mastrella
Martin Fleisher
Mike Saunders
Molly Patterson
P2860
P304
P356
10.1200/JCO.2008.20.8470
P407
P577
2009-08-03T00:00:00Z